BioCentury | Sep 3, 2019
Clinical News

Sept. 3 Clinical Quick Takes: Phase II failure for Aridis, plus Kura, Idorsia, Concert, PegBio

Aridis discontinuing antibacterial mAb Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) said AR-105 plus standard of care antibiotics missed the primary endpoint of superiority to antibiotics alone in a Phase II trial to treat ventilator-associated pneumonia (VAP) caused...
BioCentury | Aug 17, 2018
Financial News

Infectious company Aridis raises $26M in NASDAQ IPO

Infectious disease mAb company Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) raised $26 million on Aug. 13 through the sale of 2 million shares at $13 in an IPO on NASDAQ. Cantor Fitzgerald, Maxim Group, Laidlaw, Northland Securities...
BioCentury | Aug 10, 2018
Financial News

Aridis amends IPO

Immunotherapy company Aridis Pharmaceuticals Inc. (San Jose, Calif.) amended its NASDAQ IPO on Aug. 6 and now plans to sell 2 million shares at $13-$15. The offering is being underwritten by Cantor Fitzgerald, Maxim, Laidlaw,...
BioCentury | Jul 20, 2018
Financial News

Aridis proposes $34.5M IPO

Infectious disease company Aridis Pharmaceuticals Inc. (San Jose, Calif.) proposed on July 18 to raise $34.5 million in an IPO on NASDAQ underwritten by Cantor, Maxim Group and Northland Capital Markets. The company's lead candidate...
BioCentury | Mar 9, 2018
Company News

Aridis, Shenzhen Hepalink form China JV

Aridis Pharmaceuticals Inc. (San Jose, Calif.) and Shenzhen Hepalink Pharmaceutical Co. Ltd. (SZSE:002399) formed a JV -- Shenzhen Arimab Biopharmaceuticals Co. Ltd. -- to develop and gain regulatory approval of two of Aridis’ candidates, Salvecin...
BioCentury | Sep 21, 2015
Clinical News

Salvecin regulatory update

FDA granted Fast Track designation to AR-301 from Aridis to treat hospital-acquired and ventilator-associated pneumonia (HAP/VAP) caused by Staphylococcus aureus. The human IgG1 mAb against S. aureus alpha-hemolysin (aHL) generated using Aridis’ MabIgX technology is...
BioCentury | Feb 12, 2015
Targets & Mechanisms

High five for Arsanis

Researchers at Arsanis Inc. and Adimab LLC have identified an antibody that simultaneously neutralizes five Staphylococcus aureus toxins - defying the odds of hitting such diverse structures by fishing out an exposed conserved patch. While Arsanis...
Items per page:
1 - 7 of 7